Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity

被引：41

作者：

Bueno, L.

De Ponti, F.

Fried, M.

Kullak-Ublick, G. A.

Kwiatek, M. A.

Pohl, D.

Quigley, E. M. M.

Tack, J.

Talley, N. J.

机构：

[1] INRA, Neurogastroenterol Unit, F-31931 Toulouse, France

[2] Univ Bologna, Dept Pharmacol, Bologna, Italy

[3] Univ Zurich Hosp, Div Gastroenterol & Hepatol, CH-8091 Zurich, Switzerland

[4] Univ Zurich Hosp, Div Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland

[5] Natl Univ Ireland Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland

[6] Univ Louvain, Dept Gastroenterol, Louvain, Belgium

[7] Mayo Clin, Coll Med, Dyspepsia Ctr, Clin Enter Neurosci Translat & Epidemiol Res Prog, Rochester, MN USA

来源：

NEUROGASTROENTEROLOGY AND MOTILITY | 2007年 / 19卷

关键词：

abdominal pain; drugs; enteric flora; GI disorders; gut; sensitivity; serotonin;

D O I：

10.1111/j.1365-2982.2006.00876.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Visceral hypersensitivity is considered a key mechanism in the pathogenesis of functional gastrointestinal (GI) disorders. Targeting visceral hypersensitivity seems an attractive approach to the development of drugs for functional GI disorders. This review summarizes current knowledge on targets for the treatment of visceral hypersensitivity, and the status of current and future drug and probiotic treatment development, and the role of pharmacogenomic factors.

引用

页码：89 / 119

页数：31

共 260 条

[101]

Halpern GM, 1996, AM J GASTROENTEROL, V91, P1579

[102]

Hamilton-Miller J. M. T., 2001, Microbial Ecology in Health and Disease, V13, P212, DOI 10.1080/089106001753341282

[103] A SOMATOSTATIN ANALOG INHIBITS AFFERENT PATHWAYS MEDIATING PERCEPTION OF RECTAL DISTENSION [J].